Capivasertib(Truqap)

Capivasertib (trade name: TRUQAP) is a prescription oral medication approved for marketing by the U.S. Food and Drug Administration (FDA) in 2023. Its targeted indications include mutations in PIK3CA, AKT1 and PTEN, and it must be used strictly in accordance with the doctor’s instructions.

Targets

PIK3CA

AKT1

PTEN

Mechanism of Action

Capivasertib can inhibit the oncogenic signaling pathways driven by genetic variations in PIK3CA, AKT1 or PTEN.

Dosage and Administration

Route and Frequency of Administration for Capivasertib: 400 mg, oral administration, twice daily.

The dosage of Capivasertib needs to be adjusted according to the patient’s actual condition. For specific circumstances, please consult a doctor and follow the doctor’s advice closely.

Recommended Reading: Dosage and Administration of Capivasertib

Adverse Reactions

Severe Adverse Reactions: Hyperglycemia (diabetes mellitus), diarrhea, skin reactions.

Most Common Adverse Reactions: Nausea, fatigue, vomiting, oral ulcers and changes in certain blood test results.

Reference Article: Adverse Reactions of Capivasertib

Medication Use in Special Populations

Pregnancy: If you are pregnant or planning to become pregnant, Capivasertib may harm your unborn baby.

Lactation: If you are breastfeeding or planning to breastfeed, do not breastfeed during the treatment with Capivasertib. Please consult your doctor for the best way to feed your baby during the treatment with Capivasertib.

Daily Precautions

During the treatment with Capivasertib, you should not drink grapefruit juice or eat grapefruits.

from FDA，2024.09